Is Cabozantinib launched in China?

Cabozantinib (Cabozantinib) is not currently on the market in China, and therefore is not included in medical insurance. Therefore, patients cannot purchase it domestically and need to purchase it through overseas channels. There are original and generic drugs of cabozantinib abroad. The original drugs are mainly Japanese original drugs, Turkish original drugs and European version of original drugs. Foreign generic drugs are mainly Lao generic drugs and Bangladeshi generic drugs, with prices ranging from 1,300 to 2,700 yuan, and the ingredients of original drugs and generic drugs are basically the same.

Cabozantinib (Cabozantinib) is an oral targeted therapy drug that belongs to a class of drugs called multi-target tyrosine kinase inhibitors (multi-tyrosine kinase inhibitors). It can inhibit the activity of multiple tyrosine kinases, thereby interfering with the growth and spread of tumor cells.

Cabozantinib was originally approved as a treatment for thyroid cancer and renal cell carcinoma. Later, it was also used to treat other types of cancer, such as hepatocellular carcinoma and prostate cancer. The drug inhibits the growth, angiogenesis and metastasis of tumor cells by targeting receptor tyrosine kinases such as tumor growth factor receptors (such as VEGFR), MET, and RET.

Because each patient is different, their response to medications will also vary. Some side effects may occur, including but not limited to fatigue, high blood pressure, diarrhea, loss of appetite, hand-foot syndrome, etc.

Prior to treatment, doctors will assess the patient's health and cancer characteristics to determine whether cabozantinib is appropriate, and monitor responses and side effects during treatment.